You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and engaged in the emerging field of molecular medicine. The Company is focused on the discovery and development of therapeutic radiopharmaceuticals and targeted molecular imaging agents for use in oncology and cardiology. Molecular Insight has five clinical-stage candidates in development. The Company’s oncology candidates include: Azedra, Onalta Solazed, and Trofex. Zemiva, the Company’s cardiology candidate, is being developed for the diagnosis of acute myocardial ischemia.
| Ticker: | MIPI |
| ISIN: | US60852M1045 |
| Address: |
160 Second Street |
| Cambridge, MA, 02142, USA | |
| Website: | Molecular Insight Pharmaceuticals, Inc. |
| Phone #: | 617.492 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Biotechnology |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.